Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 74,555	$ 154,323
Marketable securities	474,306	558,528
Receivable from collaboration partner	0	2,587
Prepaid expenses and other current assets	16,946	10,997
Total current assets	565,807	726,435
Property and equipment, net	21,861	25,521
Operating lease right-of-use assets	25,195	27,811
Restricted cash	1,546	1,472
Other assets	7,418	6,409
Total assets	621,827	787,648
Current liabilities:
Accounts payable	3,775	4,189
Accrued clinical supply costs	5,215	5,559
Accrued liabilities	30,378	27,771
Deferred revenue, current portion	82,975	48,231
Payable to collaboration partner	7,703	0
Refund liability to collaboration partner, current portion	39,440	0
Operating lease liabilities, current portion	8,462	8,059
Total current liabilities	177,948	93,809
Deferred revenue, long-term portion	210,845	443,370
Refund liability to collaboration partner, long-term portion	67,047	0
Operating lease liabilities, long-term portion	30,456	35,268
Other long-term liabilities	1,373	759
Total liabilities	487,669	573,206
Commitments and contingencies (Note 4)
Stockholders' equity:
Common stock, $0.0001 par value; 200,000,000 shares authorized; 84,879,693 and 82,895,718 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively	8	8
Additional paid-in capital	844,044	798,696
Accumulated other comprehensive income (loss)	184	(4,575)
Accumulated deficit	(710,078)	(579,687)
Total stockholders' equity	134,158	214,442
Total liabilities and stockholders' equity	$ 621,827	$ 787,648